[
  {
    "ts": null,
    "headline": "Tracking Chase Coleman's Tiger Global Portfolio - Q3 2024 Update",
    "summary": "Tiger Global Management's 13F portfolio increased to $23.44B. Check out the notable increases, decreases, and new stakes of the portfolio here.",
    "url": "https://finnhub.io/api/news?id=c65eb2df00aa7a7d4877b9bb5cba9488c325cb6f10fa53d9e1bcae6cb491dbfe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733346402,
      "headline": "Tracking Chase Coleman's Tiger Global Portfolio - Q3 2024 Update",
      "id": 131772281,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126165968/image_1126165968.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Tiger Global Management's 13F portfolio increased to $23.44B. Check out the notable increases, decreases, and new stakes of the portfolio here.",
      "url": "https://finnhub.io/api/news?id=c65eb2df00aa7a7d4877b9bb5cba9488c325cb6f10fa53d9e1bcae6cb491dbfe"
    }
  },
  {
    "ts": null,
    "headline": "Britain drug-cost watchdog says it will recommend Lilly obesity drug",
    "summary": "Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health...",
    "url": "https://finnhub.io/api/news?id=d7c883f1a379eb6abc855b30d64fad82202ab5a44407bfb423d7881e5711a1bd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733339194,
      "headline": "Britain drug-cost watchdog says it will recommend Lilly obesity drug",
      "id": 131771398,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health...",
      "url": "https://finnhub.io/api/news?id=d7c883f1a379eb6abc855b30d64fad82202ab5a44407bfb423d7881e5711a1bd"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Flat on Biotech, Obesity-Drug Hopes -- Health Care Roundup",
    "summary": "Health Care Flat on Biotech, Obesity-Drug Hopes -- Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=425e472cd90ec2053935112ac694d50ed11da6f69555c4e7bfa6f86e656a8224",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733335560,
      "headline": "Health Care Flat on Biotech, Obesity-Drug Hopes -- Health Care Roundup",
      "id": 131774946,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Health Care Flat on Biotech, Obesity-Drug Hopes -- Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=425e472cd90ec2053935112ac694d50ed11da6f69555c4e7bfa6f86e656a8224"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s Zepbound wins the weight loss duel with Novo’s Wegovy",
    "summary": "An open- label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.",
    "url": "https://finnhub.io/api/news?id=26e8822e295706f74f108f6a83f3363377fa32a5128e5bbbda8b300f5ab1f46d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733335536,
      "headline": "Lilly’s Zepbound wins the weight loss duel with Novo’s Wegovy",
      "id": 131771749,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/22/2024/12/shutterstock_1104038513.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "An open- label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.",
      "url": "https://finnhub.io/api/news?id=26e8822e295706f74f108f6a83f3363377fa32a5128e5bbbda8b300f5ab1f46d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly stock pops: Wegovy beats Novo Nordisk rival drug in study",
    "summary": "Eli Lilly (LLY) shares gain after Zepbound, the company's weight-loss drug, outperformed rival Novo Nordisk's (NVO) competing drug, Wegovy. Yahoo Finance Reporter Akiko Fujita breaks down the study and what it means for the weight-loss drug space. To watch more expert insights and analysis on the latest market action, check out more Wealth here. This post was written by Naomi Buchanan.",
    "url": "https://finnhub.io/api/news?id=4e1dc2f6bc66b57d1beaa89df3e37482d4e5070c101da2636e69490336de0d01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733331587,
      "headline": "Eli Lilly stock pops: Wegovy beats Novo Nordisk rival drug in study",
      "id": 131771750,
      "image": "https://s.yimg.com/ny/api/res/1.2/.sACep5Hw__IMZQi0RDAYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/cd09f0c0-b260-11ef-bfef-acfb519faca9",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) shares gain after Zepbound, the company's weight-loss drug, outperformed rival Novo Nordisk's (NVO) competing drug, Wegovy. Yahoo Finance Reporter Akiko Fujita breaks down the study and what it means for the weight-loss drug space. To watch more expert insights and analysis on the latest market action, check out more Wealth here. This post was written by Naomi Buchanan.",
      "url": "https://finnhub.io/api/news?id=4e1dc2f6bc66b57d1beaa89df3e37482d4e5070c101da2636e69490336de0d01"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: UnitedHealthcare CEO Fatally Shot in Manhattan; Salesforce Tops Q3 Revenue Expectations",
    "summary": "All three major US stock indexes were up in late-morning trading Wednesday, with the Nasdaq Composit",
    "url": "https://finnhub.io/api/news?id=004cd5d45a6c19440605281ace1ec88e7556be36afb167eee69ffa80e86bcade",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733330977,
      "headline": "Top Midday Stories: UnitedHealthcare CEO Fatally Shot in Manhattan; Salesforce Tops Q3 Revenue Expectations",
      "id": 131770237,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up in late-morning trading Wednesday, with the Nasdaq Composit",
      "url": "https://finnhub.io/api/news?id=004cd5d45a6c19440605281ace1ec88e7556be36afb167eee69ffa80e86bcade"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Weight-Loss Breakthrough: Zepbound Crushes Rivals, Stock Soars Nearly 44% YTD",
    "summary": "Groundbreaking results show Zepbound outperforms Wegovy, revolutionizing obesity treatment and fueling massive investor gains.",
    "url": "https://finnhub.io/api/news?id=58635e5794f55888d67c62964a11aca416638a1a3132168940f771efd9ccb30a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733330577,
      "headline": "Eli Lilly's Weight-Loss Breakthrough: Zepbound Crushes Rivals, Stock Soars Nearly 44% YTD",
      "id": 131771752,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/ff347577c1c0d2cd942b9399fde6bc37",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Groundbreaking results show Zepbound outperforms Wegovy, revolutionizing obesity treatment and fueling massive investor gains.",
      "url": "https://finnhub.io/api/news?id=58635e5794f55888d67c62964a11aca416638a1a3132168940f771efd9ccb30a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=82de4dbac343a15cf35bfcdd368af6834527bea47645f33344da47345f51672d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733329980,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 131774947,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=82de4dbac343a15cf35bfcdd368af6834527bea47645f33344da47345f51672d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows",
    "summary": "Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows",
    "url": "https://finnhub.io/api/news?id=48f048002349e284bf464a9e35161ccf5b648918bb4af335b85287f193dbdd08",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733329200,
      "headline": "Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows",
      "id": 131774948,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows",
      "url": "https://finnhub.io/api/news?id=48f048002349e284bf464a9e35161ccf5b648918bb4af335b85287f193dbdd08"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial",
    "summary": "Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.",
    "url": "https://finnhub.io/api/news?id=fd38d97a805d3e1f4e551740b5a5820ce7b84ecec829fac75ea656e2674c0786",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733328916,
      "headline": "Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial",
      "id": 131771754,
      "image": "https://www.investopedia.com/thmb/wt_v-KxPbQdzORiI0j519QCaEbg=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2126120481-cf3f78f92bb04bce9b247dd10fbd7286.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.",
      "url": "https://finnhub.io/api/news?id=fd38d97a805d3e1f4e551740b5a5820ce7b84ecec829fac75ea656e2674c0786"
    }
  },
  {
    "ts": null,
    "headline": "Battle Of The Weight-Loss Behemoths: Eli Lilly Whomps Novo Nordisk",
    "summary": "Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head-to-head study.",
    "url": "https://finnhub.io/api/news?id=3287868e10016e7d537ab5819d3effdd0337271a1e5799ea50e9a315cce4d135",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733328628,
      "headline": "Battle Of The Weight-Loss Behemoths: Eli Lilly Whomps Novo Nordisk",
      "id": 131767340,
      "image": "https://media.zenfs.com/en/ibd.com/75c01687f70f63c85d8c90296f5e1bd1",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head-to-head study.",
      "url": "https://finnhub.io/api/news?id=3287868e10016e7d537ab5819d3effdd0337271a1e5799ea50e9a315cce4d135"
    }
  },
  {
    "ts": null,
    "headline": "Zepbound tops Wegovy for weight loss in Eli Lilly study",
    "summary": "Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.  Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy.  The drugmaker also said more patients taking Zepbound achieved at least 25% weight loss.",
    "url": "https://finnhub.io/api/news?id=4021a26ac05491ea19f67e7be4d0898db9780a22758a2e66ef8280a7105fcbfb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733325667,
      "headline": "Zepbound tops Wegovy for weight loss in Eli Lilly study",
      "id": 131767341,
      "image": "https://s.yimg.com/ny/api/res/1.2/BXdl7psr6SxMCuSGBIh5yA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-11/632d00c0-b256-11ef-851f-240487be6110",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.  Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy.  The drugmaker also said more patients taking Zepbound achieved at least 25% weight loss.",
      "url": "https://finnhub.io/api/news?id=4021a26ac05491ea19f67e7be4d0898db9780a22758a2e66ef8280a7105fcbfb"
    }
  },
  {
    "ts": null,
    "headline": "Will Trump nix Biden’s coverage plan for weight-loss drugs? It’ll be a close call.",
    "summary": "Will Trump nix Biden’s coverage plan for weight-loss drugs? It’ll be a close call.",
    "url": "https://finnhub.io/api/news?id=66d919d6ce9d3068f0704c10c32771cf5074793697b4ee6f8390cf41d9cf5a06",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733323620,
      "headline": "Will Trump nix Biden’s coverage plan for weight-loss drugs? It’ll be a close call.",
      "id": 131774949,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Will Trump nix Biden’s coverage plan for weight-loss drugs? It’ll be a close call.",
      "url": "https://finnhub.io/api/news?id=66d919d6ce9d3068f0704c10c32771cf5074793697b4ee6f8390cf41d9cf5a06"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy",
    "summary": "Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data. Click for my update on LLY and NVO.",
    "url": "https://finnhub.io/api/news?id=91ed1848203c5b53101586fafa52cf05cbd10ac8419eb23e3ce0ba46a0bad500",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733323291,
      "headline": "Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy",
      "id": 131768819,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182055972/image_182055972.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data. Click for my update on LLY and NVO.",
      "url": "https://finnhub.io/api/news?id=91ed1848203c5b53101586fafa52cf05cbd10ac8419eb23e3ce0ba46a0bad500"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly says Zepbound beat rival weight loss drug Wegovy in head-to-head study",
    "summary": "Zepbound is the “superior” choice for people looking to shed a few pounds, at least compared to Novo Nordisk’s (NVO) Wegovy, according to Eli Lilly (LLY).",
    "url": "https://finnhub.io/api/news?id=85b1ff37c0cb4e3966ec8fad9286e282555d8549ce847b8ffe1e7dddc22eb372",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733323260,
      "headline": "Eli Lilly says Zepbound beat rival weight loss drug Wegovy in head-to-head study",
      "id": 131767652,
      "image": "https://media.zenfs.com/en/quartz.com/2dcaf0da13d6dd281c82ab15895762f7",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zepbound is the “superior” choice for people looking to shed a few pounds, at least compared to Novo Nordisk’s (NVO) Wegovy, according to Eli Lilly (LLY).",
      "url": "https://finnhub.io/api/news?id=85b1ff37c0cb4e3966ec8fad9286e282555d8549ce847b8ffe1e7dddc22eb372"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly says 'Zepbound superior to Wegovy in head-to-head trial",
    "summary": "Investing.com -- Eli Lilly said Wednesday that its weight-loss medication Zepbound (tirzepatide) demonstrated superior efficacy over Novo Nordisk (NYSE:NVO)'s Wegovy (semaglutide) in the phase 3b SURMOUNT-5 trial, showing an average weight loss of 20.2% compared to Wegovy's 13.7%.",
    "url": "https://finnhub.io/api/news?id=168d1f22c4c70a892d34b28afebb62fedb2012179573fedcf0bf8eeafdde8e4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733318210,
      "headline": "Eli Lilly says 'Zepbound superior to Wegovy in head-to-head trial",
      "id": 131767342,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Eli Lilly said Wednesday that its weight-loss medication Zepbound (tirzepatide) demonstrated superior efficacy over Novo Nordisk (NYSE:NVO)'s Wegovy (semaglutide) in the phase 3b SURMOUNT-5 trial, showing an average weight loss of 20.2% compared to Wegovy's 13.7%.",
      "url": "https://finnhub.io/api/news?id=168d1f22c4c70a892d34b28afebb62fedb2012179573fedcf0bf8eeafdde8e4a"
    }
  },
  {
    "ts": null,
    "headline": "Update: Eli Lilly Says its Zepbound Showed 47% 'Greater Relative Weight Loss' Against Wegovy in Phase 3b Trial",
    "summary": "(Updates with additional details in the third, fourth and fifth paragraphs and latest stock movement",
    "url": "https://finnhub.io/api/news?id=fc1c006d5d302e2a1a1a1317b37798dfb04fad26f6a1f6c1c6a02d3408a800ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733317545,
      "headline": "Update: Eli Lilly Says its Zepbound Showed 47% 'Greater Relative Weight Loss' Against Wegovy in Phase 3b Trial",
      "id": 131767343,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Updates with additional details in the third, fourth and fifth paragraphs and latest stock movement",
      "url": "https://finnhub.io/api/news?id=fc1c006d5d302e2a1a1a1317b37798dfb04fad26f6a1f6c1c6a02d3408a800ec"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: UnitedHealthcare Executive Gunned Down In New York",
    "summary": "UnitedHealthcare CEO Brian Thompson was shot and killed this morning outside a midtown Manhattan hotel.",
    "url": "https://finnhub.io/api/news?id=5596947a803844f8a3aea40a28df4d7fe6684bbde3835903b3bc9ce33ae456e6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733314740,
      "headline": "Wall Street Lunch: UnitedHealthcare Executive Gunned Down In New York",
      "id": 131767907,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1308861166/image_1308861166.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "UnitedHealthcare CEO Brian Thompson was shot and killed this morning outside a midtown Manhattan hotel.",
      "url": "https://finnhub.io/api/news?id=5596947a803844f8a3aea40a28df4d7fe6684bbde3835903b3bc9ce33ae456e6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly stock higher following surprise weight loss treatment data",
    "summary": "Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.",
    "url": "https://finnhub.io/api/news?id=d749b2000ced38bc9dd0bed6fee3212f2dd8b5e0485edc4e75961d301590b837",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733314485,
      "headline": "Eli Lilly stock higher following surprise weight loss treatment data",
      "id": 131767658,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.",
      "url": "https://finnhub.io/api/news?id=d749b2000ced38bc9dd0bed6fee3212f2dd8b5e0485edc4e75961d301590b837"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Zepbound Beats Wegovy in Weight-Loss Drug Trial",
    "summary": "-- Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk's Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on...",
    "url": "https://finnhub.io/api/news?id=affacfddfe8a8c9c8bcf0a94c39ed148fd9b2c93907f925cc255331efd1d4047",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733314425,
      "headline": "Lilly's Zepbound Beats Wegovy in Weight-Loss Drug Trial",
      "id": 131767805,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "-- Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk's Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on...",
      "url": "https://finnhub.io/api/news?id=affacfddfe8a8c9c8bcf0a94c39ed148fd9b2c93907f925cc255331efd1d4047"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Just Got a Bundle of Good News: Time to Buy?",
    "summary": "The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ratio tops 86 -- the average for the healthcare industry is less than a quarter of that at 18.  Do recent developments make Eli Lilly's shares worth investing in despite its expensive valuation?  Eli Lilly is a leader in the weight loss sector thanks to tirzepatide, which it markets as Zepbound.",
    "url": "https://finnhub.io/api/news?id=66ca1167b8b0777437a1053795a09c46e032948796ba3ecd3f13e55419ecaace",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733314200,
      "headline": "Eli Lilly Just Got a Bundle of Good News: Time to Buy?",
      "id": 131765345,
      "image": "https://g.foolcdn.com/editorial/images/799379/physician-talking-to-patient.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ratio tops 86 -- the average for the healthcare industry is less than a quarter of that at 18.  Do recent developments make Eli Lilly's shares worth investing in despite its expensive valuation?  Eli Lilly is a leader in the weight loss sector thanks to tirzepatide, which it markets as Zepbound.",
      "url": "https://finnhub.io/api/news?id=66ca1167b8b0777437a1053795a09c46e032948796ba3ecd3f13e55419ecaace"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study",
    "summary": "People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s drug.",
    "url": "https://finnhub.io/api/news?id=7a5affe88d0fc00c0d865be4d44676bde38ab6115bdb8aea253b8c509f8de965",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733312700,
      "headline": "Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study",
      "id": 131767661,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s drug.",
      "url": "https://finnhub.io/api/news?id=7a5affe88d0fc00c0d865be4d44676bde38ab6115bdb8aea253b8c509f8de965"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy® (semaglutide). On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy.i At 72 weeks, Zepbound beat Wegovy on both the primary endpoint and all five key secondary endpoints in this trial of adults living with obesity or overweight with at least",
    "url": "https://finnhub.io/api/news?id=2138ab308bf72c2f40921db44bcb4b4f063ac329310c3842a88b99e20ad627f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733312700,
      "headline": "Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%",
      "id": 131767660,
      "image": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy® (semaglutide). On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy.i At 72 weeks, Zepbound beat Wegovy on both the primary endpoint and all five key secondary endpoints in this trial of adults living with obesity or overweight with at least",
      "url": "https://finnhub.io/api/news?id=2138ab308bf72c2f40921db44bcb4b4f063ac329310c3842a88b99e20ad627f9"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly announces the superiority of its anti-obesity treatment over that of Novo Nordisk",
    "summary": "On Wednesday, Eli Lilly published the results of a clinical study demonstrating that its Zepbound is more effective for weight loss than competitor Novo Nordisk's Wegovy.",
    "url": "https://finnhub.io/api/news?id=88d86813eb02fc09a6e5ded8fa1d5dc111219cc9d796904a2fd3ed5565c94184",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733311680,
      "headline": "Eli Lilly announces the superiority of its anti-obesity treatment over that of Novo Nordisk",
      "id": 131767428,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "On Wednesday, Eli Lilly published the results of a clinical study demonstrating that its Zepbound is more effective for weight loss than competitor Novo Nordisk's Wegovy.",
      "url": "https://finnhub.io/api/news?id=88d86813eb02fc09a6e5ded8fa1d5dc111219cc9d796904a2fd3ed5565c94184"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy",
    "summary": "Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy",
    "url": "https://finnhub.io/api/news?id=9519e983096861080675d3d93e8291e2add42d22b2a5109ba78c0fce2c67e63b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733308320,
      "headline": "Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy",
      "id": 131774950,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy",
      "url": "https://finnhub.io/api/news?id=9519e983096861080675d3d93e8291e2add42d22b2a5109ba78c0fce2c67e63b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Zepbound superior to Wegovy according to a study",
    "summary": "Eli Lilly reports initial results from the SURMOUNT-5 phase 3b randomized open-label clinical trial, according to which its Zepbound produced an average weight loss of 20.2%, 47% higher than the 13.7%...",
    "url": "https://finnhub.io/api/news?id=024604b5d4e72665c33b98cd7d5084b6854a2d87be6756811f628fa06c839e1f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733303723,
      "headline": "Eli Lilly: Zepbound superior to Wegovy according to a study",
      "id": 131766467,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly reports initial results from the SURMOUNT-5 phase 3b randomized open-label clinical trial, according to which its Zepbound produced an average weight loss of 20.2%, 47% higher than the 13.7%...",
      "url": "https://finnhub.io/api/news?id=024604b5d4e72665c33b98cd7d5084b6854a2d87be6756811f628fa06c839e1f"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial",
    "summary": "Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.",
    "url": "https://finnhub.io/api/news?id=6217e9d5c7f16f139cef6ae3ff7994ef35ed337ae334f7b2db50e9305a551e37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733300400,
      "headline": "Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial",
      "id": 131767662,
      "image": "https://imgproxy.divecdn.com/3ehcLhqBdgOjyo6HifmElEbN89bHhKVGMS2AB9ul_VY/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMDkyNDczMjEzLmpwZw==.webp",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.",
      "url": "https://finnhub.io/api/news?id=6217e9d5c7f16f139cef6ae3ff7994ef35ed337ae334f7b2db50e9305a551e37"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal",
    "summary": "Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal",
    "url": "https://finnhub.io/api/news?id=219be92a13cb3fd1cc000bade8a0bf2abb44a7e3a06ec8a2480cf83ea7271afd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733297638,
      "headline": "Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal",
      "id": 131774951,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal",
      "url": "https://finnhub.io/api/news?id=219be92a13cb3fd1cc000bade8a0bf2abb44a7e3a06ec8a2480cf83ea7271afd"
    }
  }
]